Gates Institute Executive Director Terry Fry, MD, is a professor of pediatrics, hematology and immunology, co-director of the Human Immunology and Immunotherapy Initiative, and director of Cancer Immunotherapy at the University of Colorado School of Medicine. He holds the Robert and Kathleen Clark Endowed Chair in Pediatric Cancer Therapeutics at the Children’s Hospital Colorado. Dr. Fry also serves as Head of T cell Therapeutics at Sana Biotechnology. He arrived at the University of Colorado Anschutz in 2018 after serving as head of the Hematologic Malignancies Section in the Pediatric Oncology Branch at the NIH, where he led efforts in cellular immunotherapy for pediatric leukemia. Prior to the NIH, Dr. Fry was chief of Blood and Marrow Transplantation at Children’s National Medical Center in Washington, D.C. His research focuses on the preclinical and clinical development of chimeric antigen receptor (CAR) T cells for pediatric cancers. He serves on the Committee for Scientific Affairs for the American Society of Hematology, is vice chair for biology in the Cellular Therapy Committee of the Children’s Oncology Group, and was elected into the American Society for Clinical Investigation.